Exploring controversies in lung cancer using structured pro-con debates

Suresh Senan


The past decade has witnessed many advances in the diagnosis and treatment of lung cancer. These include, but are not limited to, oncogenic driver mutations, diagnostic and functional imaging, endoscopic diagnosis, molecular pathology, oncogene targeted therapies, sub-lobar resections, image-guided and stereotactic radiotherapy, and most recently, immunotherapy. Many clinicians are hardpressed in trying to keep up with these developments. Even when results from well-conducted prospective studies are available, their findings may be difficult to translate to individual patients due stringent study inclusion criteria. Study eligibility may not account for the growing numbers of frail patients with significant co-morbidities in the general population, as well as ethnic and cultural diversity in different regions. In the present era, clinicians can benefit from critical discussions that highlight the pros and cons of new findings or existing controversies.